Press Releases

eClinical Solutions Shares Business Strategies for Accelerated Clinical Trials Post Covid-19

eClinical thought leaders to discuss decentralized trials, digital transformation of clinical research and modernized clinical data infrastructures at upcoming industry events

Crucial Data Solutions and SISCAPA Assay Technologies Partner to Introduce a New Approach to Diagnostics and Remote Health Monitoring

Together, CDS and SAT are leveraging the latest mobile and wearable technologies to achieve remote, longitudinal tracking of biomarkers in clinical trials

BOC Sciences Provides Extensive Catalog of Isotope Labeled Products

TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer

Global clinical research organization selects eClinical’s elluminate clinical data platform to optimize trial efficiency and speed

ComputaBio Has Launched Molecular Dynamics Simulation Services for Drug R&D Projects

ComputaBio, a US supplier of professional computational biology services, has launched molecular dynamics simulation services for industrial and academic customers to expedite the process of drug design.

New Healthcare Industry Survey Reveals Majority of Healthcare Organizations Unprepared for ONC Cures Act Final Rule

Albumedix Expands Production Capacity at its Commercial-Scale Recombinant Human Albumin Manufacturing Plant and Opens New Research Facilities

Albumedix Ltd., a recognised global leader in recombinant human albumin specializing in the enablement of advanced therapies, has announced the completed expansion of the company’s commercial-scale manufacturing facility, alongside the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.

CD BioSciences Reveals Its Capabilities in Conducting Proof of Concept Research

CD BioSciences, a professional US provider of integrated solutions for clinical trials development, has revealed its capabilities of conducting Proof of Concept (PoC) studies and pivotal clinical research for drug development scientists in biological and pharmaceutical institutes and companies.

THREAD Launches New Telehealth Features Expanding Video and Audio Capture for Complex eCOA during Virtual Visits in Decentralized Clinical Trials

THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), today announced the launch of new telehealth features. Building on four years of conducting electronic clinical outcome assessments (eCOA) during telehealth virtual visits, the new features raise the bar in DCT telehealth functionality by adding several unique enhancements to the company’s industry-leading eCOA and telehealth virtual visit solution. New features allow clinical study stakeholders – including sponsors, caregivers, home health professionals and raters – to remotely and safely capture video and/or audio recordings in real time.

Formulationbio Newly Launches Disintegrant Excipients for Pharmaceutical Preparation

ENPICOM and Viroclinics-DDL receive joint MIT Zuid subsidy to accelerate and improve antibody and vaccine discovery and development

ENPICOM BV, an innovative bioinformatics software engineering company, has announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application with Viroclinics-DDL, a state-of-the-art Contract Research Organization specialized in molecular diagnostic testing and assay development.

BOC Sciences Provides Extensive Catalog of Building Blocks

Thermo Fisher Scientific Collaborates with Artificial to Enhance COVID-19 Diagnostic Testing Solution

Thermo Fisher Scientific, which today announced their collaboration with Artificial to increase the productivity of COVID-19 testing through an integrated and comprehensive software automation platform.

Creative Biostructure Provides Various Vaccine Development Services for Coronavirus

Profacgen Provides Immunogenicity Testing Services to Help with Drug Discovery and Development

SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, has announced a collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

CluePoints Sponsors RBQM Live

Panthera is running a Ph 3 trial for AstraZeneca’s monoclonal antibody combination to reduce the effects of COVID-19 in patients with the virus from its North Manchester site

Panthera is enrolling Covid patients for AstraZeneca’s monoclonal antibody study to reduce disease severity

THREAD and Lokavant Partner to Provide Sponsors with First DCT Benchmarking Solution

THREAD and Lokavant partner

Alfa Chemistry Catalysts Launches Catalysts for Olefin Metathesis Reaction